🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: H2 Blocker

Found 103 matching trials

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

PHASE3

The primary objective of the study is to compare sacituzumab tirumotecan co...

Status

Recruiting

Location

Mayo Clinic in Arizona - Phoenix ( Site 0147)

Start Date

2023-12-15

Trial ID

NCT06170788

Treatments Being Tested

Sacituzumab tirumotecan Pembrolizumab Supportive care measures

Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma

N/A

To provide elotuzumab treatment for single-patient use....

Status

No Longer Available

Location

Icahn School.of Medicine at Mount Sinai

Start Date

TBD

Trial ID

NCT02541643

Treatments Being Tested

Elotuzumab

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

PHASE3

The purpose of this study is to evaluate sacituzumab tirumotecan versus pem...

Status

Active Not Recruiting

Location

Kaiser Permanente - Oakland ( Site 0054)

Start Date

2024-06-11

Trial ID

NCT06305754

Treatments Being Tested

Sacituzumab tirumotecan Pemetrexed Carboplatin H1 Receptor Antagonist H2 Receptor Antagonist Acetaminophen (or equivalent)Dexamethasone (or equivalent)Steroid Mouthwash (dexamethasone or equivalent)

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

PHASE3

This study will compare how safe and effective sacituzumab tirumotecan is v...

Status

Active Not Recruiting

Location

Banner MD Anderson Cancer Center ( Site 0119)

Start Date

2024-05-03

Trial ID

NCT06356311

Treatments Being Tested

Sacituzumab tirumotecan Trifluridine-Tipiracil Irinotecan Paclitaxel Docetaxel Rescue medications Supportive care measures

Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

PHASE2

This study is being conducted in patients with newly diagnosed breast cance...

Status

Completed

Location

Columbia University Irving Medical Center

Start Date

2012-10

Trial ID

NCT01847001

Treatments Being Tested

Propranolol DOT imaging Paclitaxel Nab-paclitaxel Trastuzumab Pertuzumab Doxorubicin Cyclophosphamide Surgery Premedication Anti-nausea therapy Pegfilgrastim

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

PHASE3

Researchers are looking for new ways to treat people with endometrial cance...

Status

Active Not Recruiting

Location

USA Mitchell Cancer Institute ( Site 4142)

Start Date

2023-12-06

Trial ID

NCT06132958

Treatments Being Tested

Sacituzumab tirumotecan Doxorubicin Paclitaxel Nab-paclitaxel Rescue medications

Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

PHASE1

Researchers are looking for new ways to treat esophageal squamous cell carc...

Status

Recruiting

Location

UPMC Hillman Cancer Center ( Site 1904)

Start Date

2025-07-30

Trial ID

NCT06780111

Treatments Being Tested

Pembrolizumab I-DXd Leucovorin Levoleucovorin 5-Fluorouracil (5-FU)Oxaliplatin Sacituzumab tirumotecan Rescue Medication

Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

PHASE2

The main goals are after treatment given before surgery, to measure the num...

Status

Recruiting

Location

Southern Cancer Center (SCC) ( Site 8004)

Start Date

2025-03-20

Trial ID

NCT06788912

Treatments Being Tested

Pembrolizumab (neoadjuvant)Cisplatin Gemcitabine Pemetrexed Sacituzumab tirumotecan H1 receptor antagonist H2 receptor antagonist Acetaminophen (or equivalent)Dexamethasone (or equivalent)Carboplatin Pembrolizumab (adjuvant)Paclitaxel Steroid mouthwash (dexamethasone or equivalent)

A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists

PHASE3

The study is a global Phase III, multicenter, randomized, double-blind, pla...

Status

Completed

Location

Multiple Locations

Start Date

2011-02

Trial ID

NCT01264939

Treatments Being Tested

Omalizumab Placebo H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist Diphenhydramine

A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection

PHASE2

Patients with HBeAG positive, chronic HBV infection will receive either ARC...

Status

Terminated

Location

Research Site 1

Start Date

2015-11

Trial ID

NCT02604212

Treatments Being Tested

ARC-520 Placebo entecavir antihistamine tenofovir

Previous Next